WASHINGTON, D.C. - Watson Pharmaceuticals Inc. agrees in its Nov. 13 response to the Federal Trade Commission's petition for a writ of certiorari that the U.S. Supreme Court should consider whether reverse-payment settlements of patent litigation between the holder of a drug patent and generic manufacturers of the drug violate federal antitrust law (Federal Trade Commission v. Watson Pharmaceuticals, Inc., et al., No. 12-416, U.S. Sup.). View related prior history, 2012 U.S. App. LEXIS 8377.